PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Abstract

This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; ClinicalTrials.gov number, NCT01876511.).

Keywords

MedicinePembrolizumabDNA mismatch repairColorectal cancerHazard ratioInternal medicineOncologyCancerImmune checkpointMicrosatellite instabilityImmune systemGastroenterologyImmunologyImmunotherapyConfidence interval

Affiliated Institutions

Related Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang , Shengqing Gu , Deng Pan +12 more

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we ...

2018 Nature Medicine 5230 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Rina Hui , Leena Gandhi , Enric Carcereny +17 more

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...

2016 Journal of Clinical Oncology 58 citations

Publication Info

Year: 2015
Type: article
Volume: 372
Issue: 26
Pages: 2509-2520
Citations: 9106
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

9106

OpenAlex

Cite This

APA Style

                            
                                
                                    Dung T. Le, 
                                
                                    Jennifer N. Uram, 
                                
                                    Hao Wang
                                
                                et al.
                            
                            (2015). 
                            PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. 
                            New England Journal of Medicine
                            , 372
                            (26)
                            , 2509-2520.
                            https://doi.org/10.1056/nejmoa1500596
                        

Identifiers

DOI: 10.1056/nejmoa1500596